Skip to content
Review

Unraveling the Intricacies of G-Protein-Coupled Receptor Signaling in Cardiovascular Diseases: Novel Perspectives From Regulation to Therapeutic Targeting.

Aug 2026 · Medicinal research reviews (Print) · 0 citations · 322 references
Medicine

TL;DR

The contributions of class A, class B, and other GPCR families to cardiovascular physiology and pathology are discussed, emphasizing their relevance to the development of targeted interventions for hypertension, heart failure, arrhythmias, atherosclerosis, and related CVDs.

Abstract

G-protein-coupled receptors (GPCRs) represent a compelling intersection of structural biology, systems pharmacology, and clinical medicine. They function as essential molecular regulators of cardiovascular physiology, governing processes from the initiation of cardiac rhythm in the sinoatrial node to the regulation of vascular tone. Their widespread expression in cardiac and vascular tissues, combined with their ability to integrate diverse extracellular signals, positions GPCRs as key regulators of heart rate, contractility, vascular tone, inflammation, and metabolic homeostasis. Recent advances in GPCR structural biology, coupled with mechanistic insights into G-protein- and β-arrestin-mediated signaling mechanisms, underscore their central role in both cardiovascular health and disease. Notably, dysregulation of GPCR signaling has emerged as a unifying mechanism across major cardiovascular diseases (CVDs), contributing to pathological remodeling, impaired contractile function, and maladaptive vascular responses. This review uniquely integrates GPCR structural biology, signaling dynamics, and mechanosensitive and biased signaling mechanisms within the cardiovascular system. We discuss the contributions of class A, class B, and other GPCR families to cardiovascular physiology and pathology emphasizing their relevance to the development of targeted interventions for hypertension, heart failure, arrhythmias, atherosclerosis, and related CVDs. Together, these insights establish a contemporary framework for advancing precision GPCR-directed therapies in CVDs. By framing these developments within a mechanistic and translational context, the review offers a timely and clinically significant resource for both basic researchers and clinicians.

View source

Similar papers

Review Open access Aug 2026

Adenosine A2A and A2B Receptors as Therapeutic Targets in Cardiovascular Diseases: Mechanistic Insights and Clinical Prospects

Adenosine is a ubiquitous endogenous modulator that coordinates diverse physiological processes by binding to specific adenosine receptors (ARs). Among the four known AR subtypes, A2ARs and A2BRs are critical determinants of cardiovascular homeostasis. This narrative review comprehensively synthesizes current knowled...

Warisara Parichatikanond, Ratchanee Duangrat, N. Nuamnaichati et al. · 0 citations
Review Aug 2026

Advances in nucleotide-based P2Y₁ antagonism: implications for cardiovascular therapeutics.

Advances in P2Y₁R signaling, pharmacology, and structure-based design are integrated, emphasizing the evolution of nucleotide antagonists and their translational potential, and insights establish P2Y₁R antagonism as a promising strategy for next-generation cardiovascular therapeutics.

N. Erathodiyil, V. Raveendran, Jackie Y. Ying · 0 citations
Sep 2026

Targeting an atypical G protein-coupled receptor signaling pathway for cardiac fibrosis therapy.

Cardiac fibrosis independently predicts adverse outcomes in heart failure (HF), yet no Food and Drug Administration-approved therapy directly targets fibrotic remodeling in the heart. To address this unmet clinical need, we used a multidimensional drug discovery pipeline centered on a human induced pluripotent stem cel...

Hao Zhang, Rabindra V. Shivnaraine, Lu Ren et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.